1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Uveal Melanoma - Pipeline Review, H2 2020, provides an overview of the Uveal Melanoma (Oncology) pipeline landscape.
Uveal melanoma, the most common intraocular tumor, is a disease in which cancer (malignant) cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these cells become cancerous, the cancer is called a melanoma. Symptoms include dark spot on the iris, glaucoma, eye pain and eye redness. Uveal melanoma is more common in people who have atypical mole syndrome, dysplastic nevus syndrome, and ocular or oculodermal melanocytosis. Treatment includes surgery, radiation and proton therapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Uveal Melanoma - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 17, 10, 12, 1 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II and Phase I stages comprises 1, 2 and 2 molecules, respectively.
Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Uveal Melanoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Uveal Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Uveal Melanoma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Uveal Melanoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Uveal Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionUveal Melanoma - Overview
Uveal Melanoma - Therapeutics Development
Uveal Melanoma - Therapeutics Assessment
Uveal Melanoma - Companies Involved in Therapeutics Development
Uveal Melanoma - Drug Profiles
Uveal Melanoma - Dormant Projects
Uveal Melanoma - Discontinued Products
Uveal Melanoma - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Uveal Melanoma, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Uveal Melanoma - Pipeline by A6 Pharmaceuticals LLC, H2 2020
- Uveal Melanoma - Pipeline by AbbVie Inc, H2 2020
- Uveal Melanoma - Pipeline by Aeglea BioTherapeutics Inc, H2 2020
- Uveal Melanoma - Pipeline by Astex Pharmaceuticals Inc, H2 2020
- Uveal Melanoma - Pipeline by Aura Biosciences Inc, H2 2020
- Uveal Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2020
- Uveal Melanoma - Pipeline by Biocon Ltd, H2 2020
- Uveal Melanoma - Pipeline by BioMed Valley Discoveries Inc, H2 2020
- Uveal Melanoma - Pipeline by Bristol-Myers Squibb Co, H2 2020
- Uveal Melanoma - Pipeline by Cleveland BioLabs Inc, H2 2020
- Uveal Melanoma - Pipeline by Delcath Systems Inc, H2 2020
- Uveal Melanoma - Pipeline by Dompe Farmaceutici SpA, H2 2020
- Uveal Melanoma - Dormant Projects, H2 2020
- Uveal Melanoma - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Uveal Melanoma, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- A6 Pharmaceuticals LLC
- AbbVie Inc
- Aeglea BioTherapeutics Inc
- Astex Pharmaceuticals Inc
- Aura Biosciences Inc
- Bellicum Pharmaceuticals Inc
- Biocon Ltd
- BioMed Valley Discoveries Inc
- Bristol-Myers Squibb Co
- Cleveland BioLabs Inc
- Delcath Systems Inc
- Dompe Farmaceutici SpA
- Exelixis Inc
- F. Hoffmann-La Roche Ltd
- Faron Pharmaceuticals Oy
- GlaxoSmithKline Plc
- Ideaya Biosciences Inc
- Immunocore Ltd
- Inventiva
- InxMed Shanghai Co Ltd
- iOnctura SA
- Iovance Biotherapeutics Inc
- Modulation Therapeutics Inc
- Novartis AG
- Okogen Inc
- Oncomatryx Biopharma SL
- OncoSpherix Inc
- PEP-Therapy SAS
- Pfizer Inc
- Plexxikon Inc
- Polaris Pharmaceuticals Inc
- Provectus Biopharmaceuticals Inc
- Regeneron Pharmaceuticals Inc
- Replimune Ltd
- Verastem Inc
- Viralytics Pty Ltd
- WPD Pharmaceuticals Inc
